Abstract. To define the factors responsible for the inactivation ofthe active fragment derived from Factor XII (Factor XIIf) in plasma, we studied the inactivation kinetics of Factor XIIf in various purified and plasma mixtures. We also analyzed the formation of '25I-Factor XIIf-inhibitor complexes by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). In purified systems, the bimolecular rate constants for the reactions ofFactor XIIfwith Cl-inhibitor, a2-antiplasmin, and antithrombin III were 18.5, 0.91, and 0.32 X 104 M-' min-, respectively. Furthermore, SDS-PAGE analysis revealed that 1:1 stoichiometric complexes were formed between 125I-Factor XIIf and each of these three inhibitors. In contrast, kinetic and SDS-PAGE studies indicated that Factor XIIf did not react with a1-antitrypsin or a2-macroglobulin.
Introduction
The active fragment derived from Factor XII (Factor XIIf)' is a serine protease (Mr 28,000) that results from proteolytic cleavage of Factor XII. This cleavage can occur on a surface, during contact activation of normal plasma (1-3), or in solution, as a consequence of Factor XII digestion by various proteolytic enzymes, including plasmin and plasma kallikrein (3) (4) (5) . In vitro, Factor XIIfis a potent liquid-phase activator ofplasma prekallikrein (6-7), which also activates Factor VII (8) , plasminogen (9) , and the first component of the classical pathway of complement (10, 1 1). However, Factor XIIf exhibits minimal clotpromoting activity (6, 7) . In vivo, severe arterial hypotension was observed after the administration to surgical patients of plasma protein fraction containing Factor XIIf (12) . This observation suggested that the circulatory collapse seen in these patients depended upon Factor XIIf-mediated plasma prekallikrein activation (12) . Direct support for this suggestion was recently obtained by the observation that increased plasma bradykinin levels were observed in patients who presented arterial hypotension as a result of the administration of plasma protein fraction that contained Factor XIIf (13) .
Studies in purified systems have shown that Factor XIIf is 1. Abbreviations used in this paper: DFP, diisopropylfluorophosphate; Factor XIMf, active fragment derived from Factor XII; p-NPGB, p-nitrophenyl p'-guanidinobenzoate HCI; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis. inactivated by several plasma protease inhibitors, including Ciinhibitor, antithrombin III, and a2-antiplasmin (14-18). Immunochemical studies have indicated that the incubation of Factor XIIf with normal plasma resulted in the formation of a complex involving Factor XIIf and Cl-inhibitor (19) . Although these investigations demonstrate that at least three plasma protease inhibitors can inactivate Factor XIIf, they do not provide a quantitative description of the factors responsible for Factor XIIf inactivation in the plasma milieu. Such an analysis is reported in this manuscript.
Methods
Materials. Dextran sulfate, CNBr-activated Sepharose 4B, quaternary aminoethyl-Sephadex A-50, Sephadex G-25 and G-75, and heparinSepharose CL-6B (Pharmacia Fine Chemicals, Uppsala, Sweden); trypsin-N-tosyl-L-phenylalanine chloromethyl ketone and soybean trypsin inhibitor (Millipore Corp., Freehold, NJ); H-D-Pro-Phe-Arg-p-nitroanilide (S-2302) (Kabi Diagnostica, Stockholm); p-nitrophenyl p'-guanidinobenzoate HCI (p-NPGB) ( (26) . Factor XIIf was radioiodinated with the Bolton-Hunter reagent (27) . Its (24) .
Antithrombin III was purchased from Kabivitrum AB (Molndal, Sweden). It was a single band of Mr 60,000 on reduced SDS-PAGE.
The concentration of active material was established by measuring its reaction with plasma kallikrein (29) .
a2-Antiplasmin was prepared using a modification (30) of the procedure described by Wiman (31) . The concentration of purified a2-antiplasmin, a single band of M, 65,000 on nonreduced SDS-PAGE, was established by titration against plasmin that had been active-site titrated with p-NPGB (32) .
al-Antitrypsin was purified as described (33) and was a gift of Dr.
H. L. James. 1 mg of this preparation completely inhibited 0.44 mg of trypsin that had been active-site titrated with p-NPGB (32) . al-Antitrypsin was a single band of Mr 54,000 on reduced SDS-PAGE.
a2-Macroglobulin was prepared as reported by Sottrup-Jensen et al. (34) . Since the resulting preparation exhibited some amidolytic activity on S-2302, it was treated with DFP (10 mM) and then extensively dialyzed. a2-Macroglobulin was predominantly a single band of Mr 185,000 on reduced SDS-PAGE. It was 85% active, as assessed by its ability to protect active site-titrated trypsin from inactivation by soybean trypsin inhibitor. Corn trypsin inhibitor, prepared as described (35), was a gift of Dr.
E. P. Kirby. This preparation was a single band of M, 18 ,000 on reduced SDS-PAGE.
Kinetic studies. Factor XIIf was incubated with various reagents in freshly silicone-coated glass vessels at 230C. Factor XIIf activity was measured by its amidolytic activity on the chromogenic substrate S-2302. A 0.6-mM solution of the substrate was prepared in 85 mM sodium phosphate buffer, pH 7.6, containing 127 mM NaCl. 10 Electrophoretic studies and autoradiography. SDS-PAGE was performed as described by Laemmli (36) , using vertical slab gels (12 X 16 X 0.15 cm) and a Protean double slab electrophoresis cell (Bio-Rad Laboratories, Richmond, CA). The concentration of acrylamide in the stacking gel was 3%, whereas it was 8.5 or 10% in the separating gel. Electrophoresis was performed at 20-40 mA/gel for 3-4 h. For autoradiography, the gels were exposed at -700C for 2.5-7 d to Typox RP-L-Film NIF films (Typon AG, Burgdorf, Switzerland) using intensifying screens.
Results
Inactivation ofFactorXlfbypurifiedplasma protease inhibitors: kinetic studies. The kinetics of inactivation of Factor Xllf amidolytic activity by various concentrations of Cl-inhibitor, antithrombin III, and a2-antiplasmin are illustrated in Figs. 1-3 .
The inactivation of Factor XIIf followed pseudo-first-order kinetics when these inhibitors were in a 3.5-to 150-fold molar excess. Pseudo-first-order rate constants, k', were obtained by dividing In 2 by the half-times of enzyme activity. Cl-inhibitor was a more efficient inhibitor of Factor XIIf than was antithrombin III or a2-antiplasmin. For example, 50% of Factor XIIf amidolytic activity was inactivated by Cl-inhibitor (2.8 pAM) in 1.5 min (Fig. 1 f) , whereas the same proportion of enzyme was inactivated in 18.8 min when antithrombin III was 11 pM (Fig. 2 b) and in 10.8 min when a2-antiplasmin was 10 puM (Fig. 3 d) (Table I) . Inactivation ofFactor XIIfby various plasmas: kinetic studies. The addition of Factor XIIf to plasma containing prekallikrein has been shown to result in the activation of prekallikrein to plasma kallikrein, i.e., in the formation of a species that exhibits amidolytic activity on S-2302. Thus, to evaluate the role of CIinhibitor and other plasma protease inhibitors in the inactivation of Factor XIIf in the plasma milieu, we studied the kinetics of inactivation of Factor XIIf amidolytic activity by prekallikreindeficient plasma. The inactivation of Factor XIIf in a 1:3.5 dilution of the plasma followed pseudo-first-order kinetics. The rate constant for the inactivation of Factor XIIf in prekallikreindeficient plasma was 14.4 X 10-2 min-' (Fig. 4, curve a) . This value was reduced to 1.8 X 10-2 min-' in plasma deficient in both prekallikrein and Cl-inhibitor (Fig. 4, curve b) . These kinetic experiments indicate that Cl -inhibitor is the predominant inhibitor of Factor XIIf in prekallikrein-deficient plasma. (Fig. 5 b) , a2-antiplasmin (Fig. 5 c) , and Clinhibitor (Fig. 5 e) resulted in the formation ofcomplexes stable in SDS with apparent Mr of 87,000, 98,000, and 145,000, respectively. These complexes contained approximately one half of the radioactivity, while the other half remained at an Mr of 28,000. This latter fraction was constant in all SDS-PAGE and seemed to represent inactive 1251-Factor XIIf. No complexes that involved '25I-Factor XIIf were formed, owing to the incubation of the radiolabeled enzyme with a1-antitrypsin (Fig.  5 d) and a2-macroglobulin (Fig. Sf) ; this is consistent with the kinetic results. Analysis of the mixture formed by the incubation of 125I-Factor XIIf with normal plasma indicated that the active label was associated with three bands with Mr of 145,000, 98,000, and 87,000 (Fig. 6 g ). These bands were identified as complexes involving Factor XIIf and Cl-inhibitor, antithrombin III, or a2-antiplasmin, since their migration patterns were identical to those exhibited by these three purified complexes, which were used as internal standards (Fig. 6, b-d) . Quantitative analysis offour experiments with normal plasma indicated that 74±1 1% (mean± 1 SD) ofthe active enzyme was forming a complex with Cl-inhibitor in this milieu, while 26±1 1% ofthe label was found in the form of complexes that involved Factor XIIf and both a2-antiplasmin and antithrombin III. 251I-Factor XIIf was also incubated with the plasma from an individual with hereditary angioedema (Fig. 6 h) . In this plasma, the fraction of active label associated with the band of Mr 145,000 was 42±12% (n = 4), while the fraction associated with the bands of Mr 98,000 and 87,000 was 58±12% (n = 4). When the radiolabeled enzyme was added to hereditary angioedema plasma that had been pretreated with antiserum to Cl-inhibitor, all the active label was found within the bands of Mr 98,000 and 87,000 (Fig. 6 i) . 1251-Factor was then incubated with plasma deficient in a2-antiplasmin (Fig. 6 j) or in antithrombin III (Fig. 6 k) . In both plasmas, the active label was predominantly associated with the band of M, 145,000 (Fig. 6 , j and k) but a small fraction of 251I-Factor XIIf migrated as a species of Mr 87,000 in a2-antiplasmin-deficient plasma (Fig. 6j) and as a species ofMr 98,000
in antithrombin III-deficient plasma (Fig. 6 k) . When '251-Factor XIIf was incubated with plasma deficient in both a2-antiplasmin and antithrombin III, the active label was entirely associated with the band ofMr 145,000 (Fig. 6, 1 (Fig. 5) . The Mr of these complexes are in good agreement with the sum of the Mr of the parent molecules, thereby indicating a 1:1 stoichiometry for the reaction between Factor XI1fand the three inhibitors. No labeled complex was formed as a consequence of the incubation of 125I-Factor XIIf with a,-antitrypsin and a2-macroglobulin (Fig. 5 ).
These latter observations strengthened our kinetic results as well as those of an earlier report (18) , which indicated that Factor
XIIfwas not inactivated by a,-antitrypsin and a2-macroglobulin.
Kinetic studies revealed that the rate constant for Factor XIIf inactivation in prekallikrein-deficient plasma was 14.4 X 10-2 min-'. This constant was in excellent agreement with the expected rate constant (15.5 X 10-2 min-') calculated using kinetic data derived from the study on the inactivation ofFactor XIIf by purified Cl-inhibitor, antithrombin III, and a2-antiplasmin (Table I ). In addition, the dominant role of Cl-inhibitor in inactivating Factor XIIf in the plasma milieu was demonstrated by the observation that the rate constant for Factor XIIf inactivation by plasma deficient in both Cl-inhibitor and prekallikrein was reduced to 13% of the rate constant observed when Factor XIIf was inactivated by prekallikrein-deficient plasma (Fig. 4) .
The preponderant role of Cl-inhibitor in the inactivation ofFactor XIIf in normal plasma was further confirmed by SDS-PAGE analysis and autoradiography of mixtures where 125i-Factor XIIf had been incubated with various plasmas (Fig. 6) . When the radiolabeled enzyme was incubated with normal plasma, it was predominantly inactivated by Cl-inhibitor (74%).
The difference from the kinetic value of >90% probably derives from the 2-h incubation period used, during which the slower inhibitors would have a chance for maximum inactivation. Similar observations were made with analysis of complexes formed between protease inhibitors and kallikrein (39) . Moreover, Ciinhibitor was still inactivating 42% ofthe active '251I-Factor XIIf in hereditary angioedema plasma, which contained 32% of the functional Cl-inhibitor of normal plasma. As previously suggested by studies in purified systems (Table I) , antithrombin III and a2-antiplasmin had a minor role in the inactivation of 1251_ Factor XIIf in normal plasma (26%), while they became more important in hereditary angioedema plasma (58%).
Cl-inhibitor is known to be the major plasma inhibitor of the proteolytic enzymes derived from the first component of complement (40) and of plasma kallikrein (21, 39), and we now report that Cl-inhibitor is also the predominant plasma inhibitor of Factor XIIf. Patients who lack Cl-inhibitor suffer from hereditary angioedema (41) and present attacks ofmucocutaneous swellings and abdominal pain that are associated with unregulated activation of the classical pathway of the complement system (42) and plasma prekallikrein (43) . Since both the first component of complement and plasma prekallikrein can be activated by Factor XIIf, we have suggested that the formation of Factor XIIf could be a central biochemical event for inducing angioedema attacks (43) . This suggestion is strengthened by the results of the present report, which demonstrate that Cl-inhibitor, the missing protein in patients with hereditary angioedema, is also the major plasma inhibitor of Factor XIIf.
